Cold-induced sweating syndrome
disease diseaseOn this page
Also known as CISS
Summary
Cold-induced sweating syndrome (MONDO:0015526) is a disease with 3 cohort genes.
At a glance
- Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
- Cohort genes: 3
- ClinVar variants: 4
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Cases/families | 6 | Worldwide | Validated | |
| Point prevalence | <1 / 1 000 000 | Worldwide | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cold-induced sweating syndrome |
| Mondo ID | MONDO:0015526 |
| OMIM | 272430 |
| Orphanet | 157820 |
| DOID | DOID:0060294 |
| ICD-11 | 1884908195 |
| SNOMED CT | 702363009 |
| UMLS | C1832409 |
| MedGen | 321950 |
| GARD | 0016983 |
| Is cancer (heuristic) | no |
Also known as: CISS
Data availability: 4 ClinVar variants · 3 GenCC gene-disease records.
Disease family
An umbrella term covering 3 Mondo subtypes.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › sensory peripheral neuropathy › hereditary sensory and autonomic neuropathy › cold-induced sweating syndrome - hyperthermia spectrum › cold-induced sweating syndrome
Subtypes (3): Cold-induced sweating syndrome 1, cold-induced sweating syndrome 2, PERCHING syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
4 retrieved; paginated sample, class counts are floors:
3 likely pathogenic, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1322162 | NM_004750.5(CRLF1):c.31_53del (p.Gln11fs) | CRLF1 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1698520 | NM_004750.5(CRLF1):c.1A>G (p.Met1Val) | CRLF1 | Likely pathogenic | criteria provided, single submitter |
| 1705180 | NM_004750.5(CRLF1):c.4_10del (p.Pro2fs) | CRLF1 | Likely pathogenic | criteria provided, single submitter |
| 3063901 | NM_004750.5(CRLF1):c.-131_21del (p.Met1fs) | CRLF1 | Likely pathogenic | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 19 · Orphanet: 10 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| CRLF1 | Definitive | Autosomal recessive | Cold-induced sweating syndrome 1 | 6 |
| CLCF1 | Strong | Autosomal recessive | cold-induced sweating syndrome 2 | 3 |
| KLHL7 | Supportive | Autosomal recessive | cold-induced sweating syndrome | 10 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| CRLF1 | Orphanet:1545 | Crisponi syndrome |
| CRLF1 | Orphanet:157820 | Cold-induced sweating syndrome |
| CRLF1 | Orphanet:930 | Idiopathic achalasia |
| KLHL7 | Orphanet:157820 | Cold-induced sweating syndrome |
| KLHL7 | Orphanet:603684 | KLHL7-related Bohring-Opitz-like and Crisponi/Cold-induced sweating-like overlap syndrome |
| KLHL7 | Orphanet:603689 | KLHL7-related Bohring-Opitz-like syndrome |
| KLHL7 | Orphanet:603694 | KLHL7-related Crisponi/cold-induced sweating-like syndrome |
| KLHL7 | Orphanet:791 | Retinitis pigmentosa |
| CLCF1 | Orphanet:1545 | Crisponi syndrome |
| CLCF1 | Orphanet:157820 | Cold-induced sweating syndrome |
Cohort genes → proteins
3 cohort genes, 3 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 3 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| CRLF1 | HGNC:2364 | ENSG00000006016 | O75462 | Cytokine receptor-like factor 1 | gencc,clinvar |
| KLHL7 | HGNC:15646 | ENSG00000122550 | Q8IXQ5 | Kelch-like protein 7 | gencc |
| CLCF1 | HGNC:17412 | ENSG00000175505 | Q9UBD9 | Cardiotrophin-like cytokine factor 1 | gencc |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| CRLF1 | Cytokine receptor-like factor 1 | In complex with CLCF1, forms a heterodimeric neurotropic cytokine that plays a crucial role during neuronal development. |
| KLHL7 | Kelch-like protein 7 | Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex. |
| CLCF1 | Cardiotrophin-like cytokine factor 1 | In complex with CRLF1, forms a heterodimeric neurotropic cytokine that plays a crucial role during neuronal development. |
Protein-family classification
Druggable: 1 · Difficult: 0 · Unknown: 2 · Druggable fraction: 0.33
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Antibody/Immunoglobulin | 1 | 9.7× | 0.199 |
| Other/Unknown | 2 | 1.2× | 0.587 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| CRLF1 | Antibody/Immunoglobulin | yes | 1.1.1.105 | FN3_dom, Ig-like_fold, Growth/epo_recpt_lig-bind |
| KLHL7 | Other/Unknown | no | BTB/POZ_dom, Kelch_1, SKP1/BTB/POZ_sf | |
| CLCF1 | Other/Unknown | no | 4_helix_cytokine-like_core, PRF/CT |
Expression context
Cohort genes with no expression data: 0.
3 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 3 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| popliteal artery | 1 |
| right coronary artery | 1 |
| tibial artery | 1 |
| heart right ventricle | 1 |
| oocyte | 1 |
| secondary oocyte | 1 |
| left uterine tube | 1 |
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| metanephros cortex | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| CRLF1 | 227 | ubiquitous | marker | right coronary artery, popliteal artery, tibial artery |
| KLHL7 | 274 | ubiquitous | marker | oocyte, secondary oocyte, heart right ventricle |
| CLCF1 | 187 | ubiquitous | marker | left uterine tube, metanephros cortex, male germ line stem cell (sensu Vertebrata) in testis |
Protein interactions among cohort
Intra-cohort edges: 2.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| KLHL7 | 1,123 |
| CRLF1 | 589 |
| CLCF1 | 491 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| CLCF1 | CRLF1 | intact, string_interaction |
| CRLF1 | KLHL7 | string_interaction |
Structural data
PDB: 3 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| CLCF1 | Q9UBD9 | 2 |
| CRLF1 | O75462 | 1 |
| KLHL7 | Q8IXQ5 | 1 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 2. Enrichment computed across 3 evidence-associated genes (2 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| IL-6-type cytokine receptor ligand interactions | 2 | 634.4× | 5e-06 | CRLF1, CLCF1 |
| Interleukin-27 signaling | 1 | 519.1× | 0.002 | CRLF1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| cell surface receptor signaling pathway via STAT | 2 | 374.5× | 1e-04 | CRLF1, CLCF1 |
| cytokine-mediated signaling pathway | 2 | 87.1× | 0.001 | CRLF1, CLCF1 |
| negative regulation of neuron apoptotic process | 2 | 73.9× | 0.001 | CRLF1, CLCF1 |
| positive regulation of isotype switching to IgE isotypes | 1 | 1404.3× | 0.003 | CLCF1 |
| negative regulation of motor neuron apoptotic process | 1 | 510.7× | 0.005 | CRLF1 |
| positive regulation of astrocyte differentiation | 1 | 468.1× | 0.005 | CLCF1 |
| positive regulation of cell population proliferation | 2 | 22.4× | 0.006 | CRLF1, CLCF1 |
| positive regulation of immunoglobulin production | 1 | 160.5× | 0.011 | CLCF1 |
| ureteric bud development | 1 | 151.8× | 0.011 | CRLF1 |
| positive regulation of B cell proliferation | 1 | 114.6× | 0.013 | CLCF1 |
| cell surface receptor signaling pathway via JAK-STAT | 1 | 96.8× | 0.014 | CLCF1 |
| B cell differentiation | 1 | 73.0× | 0.017 | CLCF1 |
| cell surface receptor signaling pathway | 1 | 21.4× | 0.053 | CLCF1 |
| proteasome-mediated ubiquitin-dependent protein catabolic process | 1 | 17.4× | 0.060 | KLHL7 |
| protein ubiquitination | 1 | 13.8× | 0.071 | KLHL7 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 3
Druggability breadth: 1 of 3 evidence-associated genes (33%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| CRLF1 | 0 | 0 |
| KLHL7 | 0 | 0 |
| CLCF1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| KLHL7 | 1 | Binding:1 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| CRLF1 | 1.1.1.105 | all-trans-retinol dehydrogenase (NAD+) |
Pharmacogenomics
Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 1 | CRLF1 |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 2 | KLHL7, CLCF1 |
Undrugged target profiles
3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| CRLF1 | 0 | — |
| KLHL7 | 1 | — |
| CLCF1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.